These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30337802)

  • 21. Novel fatty acid-binding protein 3 ligand inhibits dopaminergic neuronal death and improves motor and cognitive impairments in Parkinson's disease model mice.
    Haga H; Yamada R; Izumi H; Shinoda Y; Kawahata I; Miyachi H; Fukunaga K
    Pharmacol Biochem Behav; 2020 Apr; 191():172891. PubMed ID: 32126223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model.
    Jeon S; Kim YJ; Kim ST; Moon W; Chae Y; Kang M; Chung MY; Lee H; Hong MS; Chung JH; Joh TH; Lee H; Park HJ
    Proteomics; 2008 Nov; 8(22):4822-32. PubMed ID: 18942673
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 7,8-dihydroxyflavone Ameliorates Motor Deficits Via Suppressing α-synuclein Expression and Oxidative Stress in the MPTP-induced Mouse Model of Parkinson's Disease.
    Li XH; Dai CF; Chen L; Zhou WT; Han HL; Dong ZF
    CNS Neurosci Ther; 2016 Jul; 22(7):617-24. PubMed ID: 27079181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroprotective effect of crocin on substantia nigra in MPTP-induced Parkinson's disease model of mice.
    Haeri P; Mohammadipour A; Heidari Z; Ebrahimzadeh-Bideskan A
    Anat Sci Int; 2019 Jan; 94(1):119-127. PubMed ID: 30159851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
    Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
    J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The protective mechanism of docosahexaenoic acid in mouse model of Parkinson: The role of hemeoxygenase.
    Ozkan A; Parlak H; Tanriover G; Dilmac S; Ulker SN; Birsen I; Agar A
    Neurochem Int; 2016 Oct; ():. PubMed ID: 27984168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Echinacoside protects dopaminergic neurons by inhibiting NLRP3/Caspase-1/IL-1β signaling pathway in MPTP-induced Parkinson's disease model.
    Gao MR; Wang M; Jia YY; Tian DD; Liu A; Wang WJ; Yang L; Chen JY; Yang Q; Liu R; Wu YM
    Brain Res Bull; 2020 Nov; 164():55-64. PubMed ID: 32846198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Ginsenoside Rg1 modulates COX-2 expression in the substantia nigra of mice with MPTP-induced Parkinson disease through the P38 signaling pathway].
    Wang Q; Zheng H; Zhang ZF; Zhang YX
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(9):1594-8. PubMed ID: 18819875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage.
    Viveros-Paredes JM; Gonzalez-Castañeda RE; Escalante-Castañeda A; Tejeda-Martínez AR; Castañeda-Achutiguí F; Flores-Soto ME
    Neurologia (Engl Ed); 2019 Apr; 34(3):143-152. PubMed ID: 28104279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic activation of autophagy by combined treatment with rapamycin and trehalose in a mouse MPTP-induced model of Parkinson's disease.
    Pupyshev AB; Tikhonova MA; Akopyan AA; Tenditnik MV; Dubrovina NI; Korolenko TA
    Pharmacol Biochem Behav; 2019 Feb; 177():1-11. PubMed ID: 30582934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AAV-Mediated Expression of Dominant-Negative ULK1 Increases Neuronal Survival and Enhances Motor Performance in the MPTP Mouse Model of Parkinson's Disease.
    Balke D; Tatenhorst L; Dambeck V; Ribas VT; Vahsen BF; Michel U; Bähr M; Lingor P
    Mol Neurobiol; 2020 Feb; 57(2):685-697. PubMed ID: 31446549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of c-Jun in dopaminergic neurons of the substantia nigra in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice.
    Nishi K
    Brain Res; 1997 Oct; 771(1):133-41. PubMed ID: 9383016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease.
    Xiao-Feng L; Wen-Ting Z; Yuan-Yuan X; Chong-Fa L; Lu Z; Jin-Jun R; Wen-Ya W
    Eur J Pharmacol; 2016 Nov; 791():348-354. PubMed ID: 27614126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease.
    Pattarini R; Smeyne RJ; Morgan JI
    Neuroscience; 2007 Mar; 145(2):654-68. PubMed ID: 17258864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease.
    Sconce MD; Churchill MJ; Greene RE; Meshul CK
    Neuroscience; 2015 Jul; 299():156-74. PubMed ID: 25943481
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of ATP production ameliorates motor and cognitive impairments in a mouse model of MPTP-induced Parkinson's disease.
    Haga H; Matsuo K; Yabuki Y; Zhang C; Han F; Fukunaga K
    Neurochem Int; 2019 Oct; 129():104492. PubMed ID: 31229554
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroprotective effects of Suhexiang Wan on the in vitro and in vivo models of Parkinson's disease.
    Liu Q; Sang Heon K; Yung-Wei S; Sok Cheon P; Wonwoong L; Jongki H; Jaehwan J; Kyoung Sang C; Songhee J; Byung-Soo K
    J Tradit Chin Med; 2019 Dec; 39(6):800-808. PubMed ID: 32186150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.